测定２８例呼吸衰竭患者（呼衰组）和３２例正常对照患者（对照组）血浆血管性假血友病因子（ＶｏｎＷｉｌｌｅｂｒａｎｄＦａｃｔｏｒ．ＶＷＦ），抗凝血酶Ⅲ活性（ＡＴ—Ⅲ：ａ）抗凝血酶Ⅲ抗原（ＡＴ—Ⅲ：Ａｇ），Ⅷ因子活性（Ⅷ：Ｃ）及纤维蛋白原（Ｆｇ）。结果：呼衰组血浆Ⅷ：Ｃ，ＶＷＦ及Ｆｇ较对照组明显升高（Ｐ＜０．０１）；ＡＴ—Ⅲ：ａ、ＡＴ—Ⅲ：Ａｇ二组间无显者差异。表明：呼衰者血液处于高凝状态，其发生机理可能和促凝物质活性升高及纤溶受抑制有关，及时应用抑制促凝物质活性或促进纤溶的药物可能有助于呼衰的治疗。 Von Willebrand Factor (VFWF), antithrombin III activity (AT-III: a) were measured in 28 patients with respiratory failure (respiratory failure group) and 32 healthy controls (control group) (AT-III: Ag), factor Ⅷ activity (Ⅷ: C) and fibrinogen (Fg). Results: Plasma Ⅷ: C, VWF and Fg levels in the respiratory failure group were significantly higher than those in the control group (P <0.01). There was no significant difference in AT-Ⅲ: a and AT-Ⅲ: Ag between the two groups. The results showed that: the blood of patients with respiratory failure in hypercoagulable state, its mechanism may be related to increased procoagulant activity and fibrinolysis inhibition, timely application of anti-coagulant activity or promote fibrinolytic drugs may contribute to the treatment of respiratory failure .